Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study
Joel Lexchin
A B *
A School of Health Policy and Management, York University, 4700 Keele Street, Toronto, ON M3J 1P3, Canada.
B Faculty of Medicine, University of Toronto, Toronto, ON M5S 1AA, Canada.
Australian Health Review 46(3) 309-315 https://doi.org/10.1071/AH22008
Submitted: 19 January 2022 Accepted: 23 February 2022 Published: 5 May 2022
© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of AHHA.
Abstract
Objective Examine the use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration (TGA) for evaluating new medicines.
Methods This observational study assessed all new medicines approved by the TGA between 1 January 2018 and 18 October 2021. It examined how frequently priority and provisional approval pathways are being used, the conditions which the medicines are being approved to treat, how long medicines are spending in the approval pathways, the additional therapeutic value of the medicines being approved through these pathways and how the use of the pathways compares with similar regulatory pathways used by Health Canada.
Results The TGA approved 138 new medicines in the time period under study, of which 33 were approved through either the priority or provisional approval pathways. Sixteen were approved to treat cancer. It took the TGA a mean of 130 (95% CI 118, 143) and 144 (95% 101, 188) working days for priority and provisional pathways, respectively. Therapeutic evaluations were available for 16 of these medicines and 11 offered little to no therapeutic gain over existing medicines. There was moderate agreement between the TGA and Health Canada in their use of these pathways (Kappa = 0.5458, 95% CI 0.3900, 0.7016).
Conclusions The priority and provisional approval pathways are now being used by the TGA for about one-third of all new medicine approvals. Although the medicines approved in these ways are moving through the review process more quickly than those approved through the standard approval pathway, the majority of these medicines, for which an evaluation of therapeutic value is available, do not offer any substantial additional therapeutic value over existing medicines.
Keywords: antineoplastic agents, approval speed, Health Canada, new medicines, priority approval, provisional approval, Therapeutic Goods Administration, therapeutic value.
References
[1] Sansom L, Delaat W, Horvath J. Review of medicines and medical devices regulation: report on the regulatory framework for medicines and medical devices. 2015. Available at https://www1.health.gov.au/internet/main/publishing.nsf/Content/8ADFA9CC3204463DCA257D74000EF5A0/$File/Review%20of%20Medicines%20and%20Medical%20Devices%20-%20Recommendations_Accessible.pdf[2] Franco P. Orphan drugs: the regulatory environment. Drug Discov Today 2013; 18 163–72.
| Orphan drugs: the regulatory environment.Crossref | GoogleScholarGoogle Scholar | 22981668PubMed |
[3] Therapeutic Goods Administration. Consultation: expedited pathways for prescription medicines. Eligibility criteria and designation process. Woden, ACT; 2016. Available at https://tga.slicedtech.com.au/consultation/consultation-expedited-pathways-prescription-medicines
[4] Therapeutic Goods Administration. Consultation: Provisional Approval pathway for prescription medicines. Proposed registration process and post-market requirements. Woden, ACT: Australian Government, Department of Health, TGA; 2017.
[5] Therapeutic Goods Administration. Priority review pathway: prescription medicines. 2018. Available at https://www.tga.gov.au/priority-review-pathway-prescription-medicines
[6] Therapeutic Goods Administration. Provisional approval implementation arrangements. 2018 [1.0]. Available at https://www.tga.gov.au/sites/default/files/provisional-approval-implementation-arrangements.pdf
[7] Therapeutic Goods Administration. Prescription medicines: registration of new chemical entities in Australia. 2021. Available at https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia
[8] WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2021. Oslo: Norwegian Institute of Public Health; 2020. Available at https://www.whocc.no/atc_ddd_index/
[9] Central Intelligence Agency. The world factbook 2019. 2019. Available at https://www.cia.gov/the‐world‐factbook/
[10] Centre for Innovation in Regulatory Science. New drug approvals in six major authorities 2011-2020: focus on facilitated regulatory pathways and worksharing. London: 2021. Available at https://cirsci.org/wp-content/uploads/dlm_uploads/2021/06/CIRS-RD-Briefing-81-6-agencies-v5.pdf
[11] Government of Canada. Drug product database online query. 2021. Available at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
[12] Government of Canada. Notice of compliance - drug products. 2021. Available at https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance.html
[13] Government of Canada. Drug and vaccine authorizations for COVID-19: Overview. 2021. Available at https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization.html [updated 29 October]
[14] Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33 159–74.
| The measurement of observer agreement for categorical data.Crossref | GoogleScholarGoogle Scholar | 843571PubMed |
[15] Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ 2015; 351 h4633
| Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.Crossref | GoogleScholarGoogle Scholar | 26400751PubMed |
[16] Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med 2019; 179 906–13.
| Assessment of the clinical benefit of cancer drugs receiving accelerated approval.Crossref | GoogleScholarGoogle Scholar | 31135808PubMed |
[17] Salcher-Konrad M, Naci H, Davis C. Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. The Milbank Quarterly 2020; 98 1219–56.
| Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States.Crossref | GoogleScholarGoogle Scholar | 33021339PubMed |
